REPLIGEN CORP Operating Lease, Liability, Current
REPLIGEN CORP (RGEN) had Operating Lease, Liability, Current of $19.32 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-07-29
- 2026-06-30: Operating Lease, Liability, Current $19.32M.
- 2026-03-31: Operating Lease, Liability, Current $21.07M.
- 2025-12-31: Operating Lease, Liability, Current $21.56M.
- 2025-09-30: Operating Lease, Liability, Current $19.31M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $19.32M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $21.07M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $21.56M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $19.31M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $16.04M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $15.15M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $15.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.17M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $12.13M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $9.78M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $5.63M 10-K · filed 2025-03-14 |
| 2023-09-30 | $3.31M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $2.89M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $7.96M 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $6.96M 10-Q/A · filed 2024-11-18 |
| 2022-09-30 | $13.16M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $11.69M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $9.88M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $8.30M 10-K · filed 2023-02-22 |
| 2021-09-30 | $5.53M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $4.24M 10-Q · filed 2021-07-27 |
| 2021-03-31 | $3.77M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $5.25M 10-K · filed 2022-02-17 |
| 2020-09-30 | $4.46M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.97M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $3.75M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $3.56M 10-K · filed 2021-02-24 |
| 2019-09-30 | $3.04M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $3.29M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $3.10M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |